Brain Health in a 15-Minute Visit: What a Routine Checkup Should Cover

MedCentral asked me this week about the Alzheimer’s Association’s new Brain Health & Quality Care Initiative, a national plan to make brain health and dementia care a routine part of medical care, starting in primary care.¹ My answer was about time:

“Whether it is feasible depends on making it fit a 15- to 20-minute visit. If it adds a long checklist on top of everything else, it will struggle. If it builds on what we already do, like the Medicare annual wellness visit, it can work.”

This is the longer version: what the initiative is, what a routine visit already does for your brain, what is worth adding, and when memory changes call for more than a checkup.

What the Alzheimer’s Association announced

The Association launched the initiative on October 6, 2026.² It begins with a primary care blueprint organized around five steps: recognizing how cognitive problems first show up in the clinic, cognitive assessment, diagnostic evaluation, choosing a care pathway, and care transitions. Training, implementation tools and a recognition program for health systems are planned, and the primary care framework is due to start rolling out in January.¹ The initiative is funded by Eisai and Eli Lilly, the makers of the two approved anti-amyloid drugs.¹

The timing is not an accident. In May 2025 the FDA cleared the first blood test used in diagnosing Alzheimer’s disease, for adults 55 and older with symptoms,³ and a second test cleared that October is designed for primary care, where it helps rule Alzheimer’s out. The two anti-amyloid drugs, lecanemab (Leqembi) and donanemab (Kisunla), are approved only for the early stage, mild cognitive impairment or mild dementia. A diagnosis that comes years late can mean missing the window for treatment entirely.

The real constraint is time

A typical primary care visit lasts 15 to 20 minutes, and it is already full: blood pressure, blood sugar, refills, cancer screening, and whatever the patient actually came in for. Anything that arrives as one more long checklist gets skipped, however good the intent. A brain-health plan that works in the real world has to use what is already in the visit.

What the Medicare annual wellness visit already does

Medicare’s annual wellness visit has included “detection of any cognitive impairment” as a required element since it began in 2011.⁴ The rule does not name a test. The clinician assesses cognition by direct observation, taking into account what the patient reports and any concerns raised by family or friends. The same visit already covers several things that matter for the brain:

• A review of medications and supplements
• Risk factors for depression
• Functional ability and safety, including hearing
• Blood pressure, weight and a written prevention plan

What is often missing is structure. A brief validated tool turns an impression into a result: the Mini-Cog, a three-word recall plus a clock drawing, takes about three minutes. And when something looks off, Medicare pays for a separate, longer visit for cognitive assessment and care planning (billing code 99483), so the workup does not have to be squeezed into the wellness visit.

Most dementia risk factors are already on the list

The 2024 Lancet Commission on dementia estimated that about 45% of dementia cases are linked to 14 modifiable risk factors.⁵ Most of them are things primary care already measures and treats:

• High blood pressure. In SPRINT MIND, treating systolic pressure to below 120 rather than below 140 lowered the risk of mild cognitive impairment by about 19%.⁶
• High LDL cholesterol. Added to the list in 2024. For a fuller read on cholesterol risk, see why normal cholesterol isn’t enough.
• Diabetes and obesity. Insulin resistance often shows up years before a diabetes diagnosis; here is why fasting glucose and A1c miss it.
• Hearing and vision loss. In the ACHIEVE trial, hearing aids did not slow cognitive decline over three years in the group as a whole, but in participants at higher risk of dementia they slowed it by about 48%.⁷ Untreated vision loss was also added to the list in 2024.
• Physical inactivity. Fitness is one of the strongest predictors of healthy aging; see VO2 max and grip strength.
• Depression, smoking, heavy drinking and social isolation.

The rest of the list is less education, head injury and air pollution. Changes work best as a package. In the U.S. POINTER trial of 2,111 adults aged 60 to 79 at higher risk, a structured, coached program of exercise, diet, mental and social challenge, and regular health checks improved cognition more over two years than a self-guided version of the same advice.⁸

This is why I think building on the annual visit can work. Most of the brain-health part is not a new set of tasks. It is treating risk factors we already measure, and treating them knowing the brain is also at stake.

When memory changes need more than a checkup

Screening people who have no symptoms is still debated. In 2020 the U.S. Preventive Services Task Force concluded that the evidence is insufficient to weigh the benefits and harms of screening older adults with no signs of cognitive impairment.⁹ The picture changes when you or your family notice a change: repeating questions, getting lost on a familiar route, trouble keeping track of bills or medications, or a shift in personality. Then a fuller evaluation makes sense:

• A longer structured cognitive test, such as the MoCA
• Labs for reversible contributors, including vitamin B12 and thyroid function
• A medication review for drugs that can dull memory, such as benzodiazepines, sleep aids, older antihistamines like diphenhydramine, and bladder medications like oxybutynin
• Checks for depression, hearing loss and sleep apnea
• If Alzheimer’s is still a concern, a blood biomarker test or referral to a memory specialist to confirm the diagnosis and see whether treatment is an option

The new blood tests are for people with symptoms. The FDA clearances are for adults 55 and older with signs of cognitive decline, and the Alzheimer’s Association’s 2025 guideline on these tests covers people with cognitive impairment being evaluated in specialty care, not people who feel fine.¹⁰ A positive result in someone without symptoms is hard to act on and easy to misread.

Where a longer visit helps

Time is the bottleneck, which is the point I made to MedCentral. My initial consultations run 60 minutes or more, so a careful history, including what family members have noticed, fits in the first visit rather than being squeezed into the last two minutes. Most of the work is the same as it would be anywhere: blood pressure, ApoB and Lp(a), insulin resistance, fitness, hearing and sleep, followed over time rather than checked once a year.

The bottom line

The Alzheimer’s Association is right that brain health belongs in routine care, and new blood tests and treatments make early detection matter more than it used to. Whether the initiative works will depend on whether it fits a real visit. Building on the annual wellness visit, treating the risk factors we already measure, and having a clear next step when something seems off is achievable in primary care. If you are worried about your memory or your family history and want an unhurried look at your risk, start with a free discovery call, or read more about what a longevity doctor does.

References

1. Ede R. “Alzheimer’s Association Strategy Aims to Incorporate Brain Health in Routine Care.” MedCentral, October 19, 2026. Quotes Dr. Luke Sorrell. medcentral.com

2. Alzheimer’s Association. “Brain Health & Quality Care Initiative Launches.” October 6, 2026. alz.org

3. US Food and Drug Administration. “FDA Clears First Blood Test Used in Diagnosing Alzheimer’s Disease.” May 16, 2025. fda.gov

4. Code of Federal Regulations. 42 CFR § 410.15, “Annual wellness visits providing personalized prevention plan services.” ecfr.gov

5. Livingston G, Huntley J, Liu KY, et al. “Dementia prevention, intervention, and care: 2024 report of the Lancet standing Commission.” The Lancet 404, no. 10452 (2024): 572–628. DOI: 10.1016/S0140-6736(24)01296-0

6. SPRINT MIND Investigators; Williamson JD, Pajewski NM, et al. “Effect of Intensive vs Standard Blood Pressure Control on Probable Dementia: A Randomized Clinical Trial.” JAMA 321, no. 6 (2019): 553–561. DOI: 10.1001/jama.2018.21442

7. Lin FR, Pike JR, Albert MS, et al. “Hearing intervention versus health education control to reduce cognitive decline in older adults with hearing loss in the USA (ACHIEVE): a multicentre, randomised controlled trial.” The Lancet 402, no. 10404 (2023): 786–797. DOI: 10.1016/S0140-6736(23)01406-X

8. Baker LD, Espeland MA, Whitmer RA, et al. “Structured vs Self-Guided Multidomain Lifestyle Interventions for Global Cognitive Function: The US POINTER Randomized Clinical Trial.” JAMA 334, no. 8 (2025): 681. DOI: 10.1001/jama.2025.12923

9. US Preventive Services Task Force. “Screening for Cognitive Impairment in Older Adults: US Preventive Services Task Force Recommendation Statement.” JAMA 323, no. 8 (2020): 757–763. DOI: 10.1001/jama.2020.0435

10. Palmqvist S, Whitson HE, Allen LA, et al. “Alzheimer’s Association Clinical Practice Guideline on the use of blood-based biomarkers in the diagnostic workup of suspected Alzheimer’s disease within specialized care settings.” Alzheimer’s & Dementia 21, no. 7 (2025): e70535. DOI: 10.1002/alz.70535